Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens

Vaccine

Volumn 28, Issue 5, 2010, Pages 1294-1299

  Lee, Lucy F ^a   Kreager, K S ^b   Arango, J ^b   Paraguassu, A ^b   Beckman, B ^b   Zhang, Huanmin ^a   Fadly, Aly ^a   Lupiani, B ^c   Reddy, S M ^c  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b Hy Line International   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Marek's disease virus; MD vaccine; Meq oncogene; Recombinant MDV

Indexed keywords

BIVALENT VACCINE HVT SB 1; HERPES VACCINE; HVT VACCINE; MAREK DISEASE VACCINE; RISPEN VACCINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIRD DISEASE; CHICKEN; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; FEMALE; INOCULATION; MALE; MARDIVIRUS; MEQ ONCOGENE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SEROTYPE; VIRUS STRAIN;

ANIMALS; CELLS, CULTURED; CHICKENS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DUCKS; GENE DELETION; MARDIVIRUS; MAREK DISEASE; MAREK DISEASE VACCINES; ONCOGENE PROTEINS, VIRAL; POULTRY DISEASES;

EID: 74149094202     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.022     Document Type: Article

References (39)

1. Churchill A.E., and Biggs P.M. Agent of Marek's disease in tissue culture. Nature 215 July (100) (1967) 528-530
2. Nazerian K., Solomon J.J., Witter R.L., and Burmester B.R. Studies on the etiology of Marek's disease. II. Finding of a herpesvirus in cell culture. Proc Soc Exp Biol Med 127 (1968) 177-182
3. Buckkmaster A.E., Scott S.D., Sanderson M.J., Boursnell M.E.G., Ross L.J.N., and Binns M.M. Gene sequence and mapping data from Marek's disease virus and herpesvirus of turkeys: implication for herpesvirus classification. J Gen Virol 69 (1988) 2033-2042
4. Lee L.F., Wu P., Sui P.D., Ren D., Kamil J., Kung H.J., et al. The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus. Proc Natl Acad Sci 97 (2000) 6091-6096
5. Tulman E.R., Afonso C.L., Lu Z., Zsak L., Rock D.L., and Kutish G.F. The genome of a very virulent Marek's disease virus. J Virol 74 (2000) 7980-7988
6. Bülow V.v., and Biggs P.M. Differentiation between strains of Marek's disease virus and turkey herpesvirus by immunofluorescence assays. Avian Pathol 4 (1975) 133-146
7. Lee L.F., Liu X., and Witter R.L. Monoclonal antibodies with specificity for three different serotypes of Marek's disease viruses in chickens. J Immunol 130 (1983) 1003-1006
8. Witter R.L., Calnek B.W., Buscaglia C., Gimeno I.M., and Schat K.A. Classification of Marek's disease viruses according to pathotype: philosophy and methodology. Avian Pathol 34 2 (2005 Apr) 75-90
9. Witter R.L., Nazerian K., Purchase H.G., and Burgoyne G.H. Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek's disease virus. Am J Vet Res 31 3 (1970) 525-538
10. Schat K.A., and Calnek B.W. Characterization of an apparently nononcogenic Marek's disease virus. J Natl Cancer Inst 60 May (5) (1978) 1075-1082
11. Rispens B.H., van V.H., Mastenbroek N., Maas H.J., and Schat K.A. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis 16 April (1) (1972) 108-125
12. Rispens B.H., van V.H., Mastenbroek N., Maas J.L., and Schat K.A. Control of Marek's disease in The Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus. Avian Dis 16 April (1) (1972) 126-138
13. Witter R.L. Increased virulence of Marek's disease virus field isolates. Avian Dis 41 1 (1997) 149-163
14. Gimeno I.M. Marek's disease vaccines: a solution for today but a worry for tomorrow?. Vaccine 26 July (Suppl. 3) (2008) C31-C41
15. Witter R.L., and Kreager K.S. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease. Avian Dis 48 4 (2004) 768-782
16. Jones D., Lee L., Liu J.L., Kung H.J., and Tillotson J.K. Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors. Proc Natl Acad Sci USA 89 9 (1992) 4042-4046
17. Kung H.J., Xia L., Brunovskis P., Li D., Liu J.L., and Lee L.F. Meq: an MDV-specific bZIP transactivator with transforming properties. Curr Top Microbiol Immunol 255 (2001) 245-260
18. Liu J.L., Lee L.F., Ye Y., Qian Z., and Kung H.J. Nucleolar and nuclear localization properties of a herpesvirus bZIP oncoprotein, MEQ. J Virol 71 4 (1997 Apr) 3188-3196
19. Qian Z., Brunovskis P., Rauscher III F., Lee L.F., and Kung H.J. The transactivation activity of meq, a Marek's disease herpes virus b-ZIP protein persistently expressed in latently-infected transformed T-cells. J Virol 69 (1995) 4037-4044
20. Liu J.L., Ye Y., Lee L.F., and Kung H.J. Transforming potential of the herpesvirus oncoprotein MEQ: morphological transformation, serum-independent growth, and inhibition of apoptosis. J Virol 72 January (1) (1998) 388-395
21. Liu J.L., Ye Y., Qian Z., Qian Y., Templeton D.J., Lee L.F., et al. Functional interactions between herpesvirus oncoprotein MEQ and cell cycle regulator CDK2. J Virol 73 (1999) 4208-4219
22. Levy A.M., Gilad O., Xia L., Izumiya Y., Choi J., Tsalenko A., et al. Marek's disease virus Meq transforms chicken cells via the v-Jun transcriptional cascade: a converging transforming pathway for avian oncoviruses. Proc Natl Acad Sci USA 102 October (41) (2005) 14831-14836
23. Levy A.M., Izumiya Y., Brunovskis P., Xia L., Parcells M., Reddy S.M., et al. Characterization of the chromosomal binding sites and dimerization partners of the viral oncoprotein Meq in Marek's disease virus-transformed T cells. J Virol 77 December (23) (2003) 12841-12851
24. Lupiani B., Lee L.F., Cui X., Gimeno I., Anderson A., Morgan R.W., et al. Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication. Proc Natl Acad Sci USA 101 32 (2004) 11815-11820
25. Lee L.F., Lupiani B., Silva R.F., Kung H.J., and Reddy S.M. Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV. Vaccine 26 March (15) (2008) 1887-1892
26. Witter R.L., Lee L.F., and Fadly A.M. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus. Avian Dis 39 (1995) 269-284
27. Reddy S.M., Lupiani B., Gimeno I.M., Silva R.F., Lee L.F., and R.L. Witter R.L. Rescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: use of a pp38 mutant to validate the technology for the study of gene function. Proc Natl Acad Sci USA 99 (2002) 7054-7059
28. Geng S., and Hills F.J. Biometrics in agriculture science (1989), Kendall/Hunt Publishing Comparny, Dubuque, Iowa, USA
29. Bacon L.D., and Witter R.L. Influence of B-haplotype on the relative efficacy of Marek's disease vaccines of different serotypes. Avian Dis 37 January (1) (1993) 53-59
30. Bacon L.D., and Witter R.L. B haplotype influence on the relative efficacy of Marek's disease vaccines in commercial chickens. Poult Sci 73 April (4) (1994) 481-487
31. Bacon L.D., and Witter R.L. Serotype specificity of B-haplotype influence on the relative efficacy of Marek's disease vaccines. Avian Dis 38 January (1) (1994) 65-71
32. King D., Page D., Schat K.A., and Calnek B.W. Difference between influences of homologous and heterologous maternal antibodies on response to serotype-2 and serotype-3 Marek's disease vaccines. Avian Dis 25 January (1) (1981) 74-81
33. Sharma J.M., and Graham C.K. Influence of maternal antibody on efficacy of embryo vaccination with cell-associated and cell-free Marek's disease vaccine. Avian Dis 26 October (4) (1982) 860-870
34. Witter R.L., and Lee L.F. Polyvalent Marek's disease vaccines: safety, efficacy and protective synergism in chickens with maternal antibodies. Avian Pathol 13 January (1) (1984) 75-92
35. Witter R.L., and Burmester B.R. Differential effect of maternal antibodies on efficacy of cellular and cell-free Marek's disease vaccines. Avian Pathol 8 April (2) (1979) 145-156
36. Islam A.F., Walkden-Brown S.W., Groves P.J., and Underwood G.J. Effects of vaccine dose, virus challenge dose and interval from vaccination to challenge on protection of broiler chickens against Marek's disease virus challenge. Aust Vet J 85 September (9) (2007) 348-355
37. Witter R.L., Xharma J.M., and Fadly A.M. Pathogenicity of variant Marek's disease virus isolants in vaccinated and unvaccinated chickens. Avian Dis 24 (1980) 210-232
38. Witter R.L. Protective efficacy of Marek's disease vaccines. Curr Top Microbiol Immunol 255 (2001) 57-90
39. Fakhrul Islam A.F., Walkden-Brown S.W., Groves P.J., and Underwood G.J. Kinetics of Marek's disease virus (MDV) infection in broiler chickens 1: effect of varying vaccination to challenge interval on vaccinal protection and load of MDV and herpesvirus of turkey in the spleen and feather dander over time. Avian Pathol 37 June (3) (2008) 225-235